Pharma & Life Sciences
Royalty Pharma
As Chairman and founder of Royalty Pharma, Rory Riggs helped create the pharmaceutical royalty asset class — building the company from a $60 million start in 1996 to the world’s largest acquirer of pharmaceutical royalties, $26 billion at 2026, with partial royalty rights on seven of the top thirty drugs sold in the United States.
A portfolio of life-sciences foundings
Riggs was a founder or early-stage investor in SUGEN, BioMatrix, FibroGen, and Intra-Cellular Therapies, and served as a director of each — the same pattern applied across a thirty-year career: identify a domain where the right system does not yet exist, then build it.
See the Coordinate System for the underlying framework, or About for Riggs’s full board and governance record.